Table 3.
Analysis of the diagnostic efficiency of selected sphingolipids that significantly differentiated patients with and without cholelithiasis.
| Marker | AUC | 95% C.I. AUC | p | Cut-Off | Sensit. | Spec. | ACC |
|---|---|---|---|---|---|---|---|
| SPA | 0.326 | (0.211–0.442) | 0.003 | 1.107 | 100% | 26% | 57.0% |
| C14:0-Cer | 0.99 | (0.971–1.0) | <0.001 | 1.363 | 95.8% | 97.4% | 96.5% |
| C16:0-Cer | 1 | (1.0–1.0) | <0.001 | 59.692 | 97.9% | 100% | 98.8% |
| C20:0-Cer | 0.914 | (0.857–0.972) | <0.001 | 26.83 | 93.8% | 73.7% | 84.9% |
| C24:1-Cer | 0.656 | (0.533–0.778) | 0.01 | 406.594 | 77.1% | 60.5% | 69.8% |
| C16:0-LacCer | 0.721 | (0.615–0.827) | <0.001 | 1536.383 | 50% | 92.1% | 68.6% |
| C18:1-LacCer | 0.888 | (0.819–0.957) | <0.001 | 21.977 | 89.6% | 78.9% | 84.9% |
| C24:1-LacCer | 0.876 | (0.804–0.948) | <0.001 | 749.27 | 65.8% | 93.8% | 81.4% |
| C24:0-LacCer | 0.93 | (0.88–0.979) | <0.001 | 250.785 | 73.7% | 95.8% | 86.0% |
SPA—sfinganine; Cer—ceramide, LacCer—lactosylceramide AUC—area under the curve; C.I-confidence interval; Sensit.—sensitivity; Specific.—specificity; ACC—accuracy.